Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dapagliflozin in STEMI
Sponsor: Ottawa Heart Institute Research Corporation
Summary
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Official title: The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
256
Start Date
2025-01-20
Completion Date
2027-12
Last Updated
2026-02-20
Healthy Volunteers
No
Interventions
Dapagliflozin 10mg Tab
Dapagliflozin 10 mg daily X 7 days
CMR
CMR 3-5 days post randomization
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada